TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)-Reference-Cited by-同舟云学术

TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)

Published:2018-10 Issue: Volume:29 Page:viii715
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cremolini C.,Antoniotti C.,Lonardi S.,Rossini D.,Pietrantonio F.,Cordio S.S.,Murgioni S.,Marmorino F.,Maiello E.,Passardi A.,Masi G.,Tamburini E.,Santini D.,Grande R.,Zaniboni A.,Granetto C.,Loupakis F.,Delliponti L.,Boni L.,Falcone A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy424.021/26140294/mdy424.021.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial;BMJ Open;2022-04

2. Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group;Clinical Colorectal Cancer;2021-09

3. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies;Annals of Oncology;2019-12

4. Faut-il prendre en compte la localisation du primitif dans la prise en charge du cancer colorectal métastatique ?;Côlon & Rectum;2019-05

5. Does Sidedness Matter in Unresectable Colorectal Cancer?;Annals of Surgical Oncology;2019-03-18